Explore the words cloud of the CVDTEU project. It provides you a very rough idea of what is the project "CVDTEU" about.
The following table provides information about the project.
BIOVICA INTERNATIONAL AB
|Coordinator Country||Sweden [SE]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2014-11-01 to 2015-02-28|
Take a look of project's partnership.
|1||BIOVICA INTERNATIONAL AB||SE (UPPSALA)||coordinator||50˙000.00|
Many cancer therapies fail due to inadequate prediction of patient-specific treatment responses. In addition, a large number of clinical trials fail due to a lack of predictive tools for optimal cohort selection. Biovica has developed a sensitive and precise assay for the measurement of a biomarker thymidine kinase (TK) from serum as an indicator of cell proliferation. Our assay technology has been clinically tested and has demonstrated beyond state-of-the-art capability compared to existing solutions due to its unprecedented sensitivity. This allows for previously unrealized capabilities in monitoring and prediction of therapy response for most common cancers. The unique selling point of our technology is the documented ability to reliably measure solid tumor proliferation from serum, thereby making it cheaper, more scalable and less invasive for the patient than industry standards. Our key customers are drug developers and clinicians who will use it for optimal cohort selection for clinical trials, and prediction of treatment response for patients respectively. However, in order to reach these customers, we require carrying out extensive clinical validations to demonstrate technological soundness. Europe represents the largest market for biomarker diagnostics due to a growing ageing population. We therefore aim to conduct clinical studies in key European markets with access to relevant bio-banks. In phase 1 of the proposed project, we will perform a feasibility study with focus on market related activities in Europe. Thereafter we aim to conduct clinical studies in selected European countries in partnership with clinicians. Our ambition is to become the industry standard for cancer proliferation measurement worldwide.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CVDTEU" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CVDTEU" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
ENDOSCAPE, a clinically applicable non-viral gene delivery technologyRead More
Childhood Leukemia: Overcoming distance between South America and Europe RegionsRead More